Pioneering single-dose radiotherapy for breast cancer treatment

2021-05-28

(Press-News.org) A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional radiotherapy, and avoids potential damage to nearby organs, according to a paper by UCL experts.

The results, published in the British Journal of Cancer, mean that eight out of ten patients who receive the treatment, TARGIT-IORT, will not need a long course of post-operative external beam radiotherapy (EBRT). These results strengthen and expand previously published outcomes.

Patients who received the treatment are less likely to go on to experience fatal cardiovascular disease such as heart attacks, lung problems or other cancers. As well as avoiding scattered radiation from EBRT that can damage nearby vital organs, delivering TARGIT-IORT during the lumpectomy procedure seems to lower the likelihood of death if patients do go on to develop cardiovascular disease, protecting in a drug-like manner. This was the case even when EBRT was also given post-operatively, and is thought to be because the treatment changes the microenvironment in the lumpectomy wound.

The researchers say that delivering radiation immediately to the site where the tumour was can reduce the adverse effects of surgical trauma make the site less conducive for cancer growth and could have an 'abscopal' (distant) effect. This is where a treatment such as radiotherapy has a positive effect on tissue away from the operation site, which is increasingly recognised as a beneficial immunological action. Previous studies have shown that the treatment has fewer radiation-related side effects compared with conventional whole breast radiotherapy, with less pain, a superior cosmetic outcome with fewer changes to the breast as a whole and a better quality of life.

Lead author Professor Jayant Vaidya (UCL Surgery & Interventional Science) said: "With TARGIT-IORT, women can have their surgery and radiation treatment for breast cancer at the same time. This reduces the amount of time spent in hospital and enables women to recover more quickly, meaning they can get back to their lives more quickly."

TARGIT-IORT is delivered immediately after tumour removal (lumpectomy), and under the same anaesthetic, via a small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases. Further tumour subgroup analysis also found that there was a significant overall survival benefit with TARGIT-IORT in patients with grade 1 or 2 cancer.

Professor Vaidya added: "These new results make it clear that the TARGIT-IORT is effective in all tumour subgroups of invasive duct cancer, the most common type of breast cancer. Our new online tool can help clinicians make a decision about additional radiotherapy (recommended in a small proportion of cases) for each individual patient.

"The finding that fewer deaths are from the avoidance of scattered radiation and the possible abscopal effect of TARGI-IORT is important and should fuel further research, opening doors to new treatments."

For the clinical trial, which started in March 2000, 2,298 women aged 45 or over with invasive breast cancer and a tumour up to 3.5cm in diameter were randomly assigned to receive either TARGIT-IORT during lumpectomy or post-operative EBRT. The trial was designed and run from UCL, involved 32 hospitals and medical centres in ten countries: the UK, France, Germany, Italy, Norway, Poland, Switzerland, the USA, Canada and Australia.

Professor Michael Baum (UCL Surgery & Interventional Science) said: These results are the highest level of evidence proving not only the effectiveness of TARGIT-IORT but confirming that it avoids deaths from other causes.

"The new data is biologically very interesting and the new tools will make its application in routine clinical practice much easier. I am pleased that it will benefit thousands of breast cancer patients around the world."

Professor Jeffrey S Tobias (Professor of Clinical Oncology, UCL and UCLH) said: With "TARGIT-IORT, the majority of patients presenting with early localised breast cancer will never need any further radiotherapy.

"They will avoid all the side effects of whole breast radiotherapy. The chance of remaining free of local recurrence (in the breast itself) is the same as with traditional treatment, but our new analysis shows that even if they do get a local relapse, it will not detract from an excellent prognosis - as good as not having a relapse - a rather different state of affairs from the more serious outlook if this were to happen after EBRT."

To date, 45,000 patients in 260 centres in 38 countries have received TARGIT-IORT). The clinicians hope that following the latest results, more patients can be offered the treatment both in the UK and around the world instead of EBRT.

INFORMATION:

Additional material:

Paper published in the British Medical Journal in 2020, upon which this paper expands: https://www.bmj.com/content/370/bmj.m2836.full.pdf

A short video explanation: https://youtu.be/w0OMjVfJ5pY

An explanatory blog: https://go.nature.com/3ymrplc

For more information about the treatment: https://targit.org.uk/

Funding for the trial was provided by the National Institute for Health Research (NIHR) Health Technology Assessment Programme, UCL Comprehensive Biomedical Research Centre and Cancer Research UK.

Notes to Editors

For more information or to speak to the researchers involved, please contact

Jane Bolger, UCL Media Relations. T: +44 (0) 20 3108 9040 / +44 (0)7733 261 477. E: j.bolger@ucl.ac.uk

Professor Jayant Vaidya. T; +44 7801418072 and Prof Tobias +44 7814702063 Jayant S. Vaidya, Max Bulsara, Michael Baum, Frederik Wenz, Samuele Massarut, Steffi Pigorsch, Michael Alvarado, Michael Douek, Christobel Saunders, Henrik Flyger, Wolfgang Eiermann, Chris Brew-Graves, Norman R. Williams, Ingrid Potyka, Nicholas Roberts, Marcelle Bernstein, Douglas Brown, Elena Sperk, Siobhan Laws, Marc Sütterlin, Tammy Corica, Steinar Lundgren, Dennis Holmes, Lorenzo Vinante, Fernando Bozza, Montserrat Pazos, Magali Le Blanc-Onfroy, Günther Gruber, Wojciech Polkowski, Konstantin J. Dedes, Marcus Niewald, Jens Blohmer, David McReady, Richard Hoefer, Pond Keleman, Gloria Petralia, Mary Falzon, David Joseph, Jeffrey S. Tobias, 'New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer' is published in British Journal of Cancer.

The DOI for this paper is https://doi.org/10.1038/s41416-021-01440-8

About UCL (University College London) - London's Global University

UCL is a diverse community with the freedom to challenge and think differently.

Our community of more than 41,500 students from 150 countries and over 12,500 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.

We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.

We have a progressive and integrated approach to our teaching and research - championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.

For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.

We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.

http://www.ucl.ac.uk| Follow @uclnews on Twitter | Watch our YouTube channel | Listen to UCL podcasts on SoundCloud | Find out what's on at UCL Minds | #MadeAtUCL Find out how UCL is helping lead the global fight against COVID-19 http://www.ucl.ac.uk/covid-19-research

ELSE PRESS RELEASES FROM THIS DATE:

Watch me move it, move it: Gliding structure in Mycoplasma mobile revealed

2021-05-28

Much of human invention and innovation has been the result of our discovery and replication of natural phenomena, from birds serving to inspire human flight, to whales allowing us to dive deep into the ocean with submarines. For the first time ever, researchers have captured at the nanometer level the gliding machinery of the bacterium Mycoplasma mobile. Their findings were published in mBio. This brings us closer to understanding the origin and operating principle of motility, which could serve as a basis for the next generation of nanoscale devices and pharmaceuticals. "My lab has been studying the molecular nature of bacteria from the Mycoplasma genus for years", ...

Research shows potential new sunscreen is coral-safe and provides more UVB/UVA protection

2021-05-28

(Bethesda, MD - May 25, 2021) A new study published in Nature Scientific Reports has found that Methylene Blue, a century old medicine, has the potential to be a highly effective, broad-spectrum UV irradiation protector that absorbs UVA and UVB, repairs ROS and UV irradiation induced DNA damages, and is safe for coral reefs. The study suggests that Methylene Blue could become an alternative sunscreen ingredient that supports the environment and protects human skin health.80% of today's sunscreens use Oxybenzone as a chemical UV blocker, despite multiple studies that have shown it expedites the destruction of coral reefs. Several states and countries have now banned the use of Oxybenzone and its derivatives to stop the devastating ...

How retroviruses become infectious

2021-05-28

Viruses are perfect molecular machines. Their only goal is to insert their genetic material into healthy cells and thus multiply. With deadly precision, they thereby can cause diseases that cost millions of lives and keep the world on edge. One example for such a virus, although currently less discussed, is HIV that causes the ongoing global AIDS-epidemic. Despite the progress made in recent years, 690 000 people died in 2019 alone as a result of the virus infection. "If you want to know the enemy, you have to know all its friends," says Martin Obr, postdoc at the Schur group at IST Austria. Together with his colleagues, he therefore studies a virus belonging to the same ...

Blood test detects childhood tumors based on their epigenetic profiles

2021-05-28

A new study exploits the characteristic epigenetic signatures of childhood tumors to detect, classify and monitor the disease. The scientists analyzed short fragments of tumor DNA that are circulating in the blood. These "liquid biopsy" analyses exploit the unique epigenetic landscape of bone tumors and do not depend on any genetic alterations, which are rare in childhood cancers. This approach promises to improve personalized diagnostics and, possibly, future therapies of childhood tumors such as Ewing sarcoma. The study has been published in Nature Communications. A study led by scientists from St. Anna Children's Cancer Research Institute (St. Anna CCRI) in collaboration with CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences provides an innovative ...

Solving a double murder arouses international interest

2021-05-28

The technology using DNA-based genealogy that solved a double murder in Linköping opens completely new possibilities in investigating serious crime. LiU researchers are now involved in spreading new knowledge about the technology, which brings hope to police forces and has aroused major international interest. "We want to tell others about the problems that we faced when working with this pilot case, and how we dealt with them. We can prevent others reinventing the wheel, and make sure that the knowledge available is extended and improved", says Andreas Tillmar. He is forensic geneticist at the National Board of Forensic Medicine, and adjunct senior lecturer ...

Data from 45 million mobile users further shows poorer people less able to stay at home COVID rules

2021-05-28

People living in deprived, less affluent neighborhoods spent less time indoors at home during lockdown, according to a study that tracked data from millions of mobile phone users across the United States. The study, published in the journal Annals of the American Association of Geographers, adds to growing evidence that low earners are less likely to comply with stay-at-home orders, either because they simply can't afford to, or because they work in professions in which working from home is not possible. The finding is concerning given the fact that vulnerable groups are already at greater risk from COVID. In March 2020, the US like many countries in the world entered a state of lockdown, with its citizens advised to stay at home to curb the spread of Coronavirus. Non-essential ...

Plastic in Galapagos seawater, beaches and animals

2021-05-28

Plastic pollution has been found in seawater, on beaches and inside marine animals at the Galapagos Islands. A new study - by the University of Exeter, Galapagos Conservation Trust (GCT) and the Galapagos Science Center - found plastic in all marine habitats at the island of San Cristobal, where Charles Darwin first landed in Galapagos. At the worst "hotspots" - including a beach used by the rare "Godzilla" marine iguana - more than 400 plastic particles were found per square metre of beach. Plastic was also found inside more than half of the marine invertebrates (such as barnacles and urchins) studied, and on the seabed. The findings suggest most plastic pollution in Galapagos - a world-famous biodiversity haven - arrives on ocean currents. The study also ...

When to release free and paid apps for maximal revenue

2021-05-28

Researchers from Tulane University and University of Maryland published a new paper in the Journal of Marketing that examines the dynamic interplay between free and paid versions of an app over its lifetime and suggests a possible remedy for the failure of apps. The study, forthcoming in the Journal of Marketing, is titled "Managing the Versioning Decision over an App's Lifetime" and is authored by Seoungwoo Lee, Jie Zhang, and Michel Wedel. Is it really over for paid mobile apps? The mobile app industry is unique because free apps are much more prevalent than paid apps in most app categories, contrary to many other product markets where free products primarily play a supportive role to the paid products. Apps have been trending toward the free version in the past decade, such ...

Helping doctors manage COVID-19

2021-05-28

Artificial intelligence (AI) technology developed by researchers at the University of Waterloo is capable of assessing the severity of COVID-19 cases with a promising degree of accuracy. A study, which is part of the COVID-Net open-source initiative launched more than a year ago, involved researchers from Waterloo and spin-off start-up company DarwinAI, as well as radiologists at the Stony Brook School of Medicine and the Montefiore Medical Center in New York. Deep-learning AI was trained to analyze the extent and opacity of infection in the lungs of COVID-19 patients based on chest x-rays. Its scores were then compared to assessments of the ...

Next-gen electric vehicle batteries: These are the questions we still need to answer

2021-05-28

The next generation of electric vehicle batteries, with greater range and improved safety, could be emerging in the form of lithium metal, solid-state technology. But key questions about this promising power supply need to be answered before it can make the jump from the laboratory to manufacturing facilities, according to University of Michigan researchers. And with efforts to bring electric vehicles to a larger part of the population, they say, those questions need answering quickly. Jeff Sakamoto and Neil Dasgupta, U-M associate professors of mechanical engineering, have been leading researchers on lithium metal, solid-state batteries over the past decade. In ...

LAST 30 PRESS RELEASES:

Artificial intelligence enhances monitoring of threatened marbled murrelet

The solution to kidney bleeding and recovery lies within a hemostasis sponge, using the inherent capabilities of the kidneys

The Lancet Public Health: Global study reveals stark differences between females and males in major causes of disease burden, underscoring the need for gender-responsive approaches to health